About Lung Cancer Journey

The Lung Cancer Journey is a multifaceted exploration of lung cancer and its impact on patients, research, therapy, finances, and policy. Join us as we examine the latest advances and controversies in the diagnosis and treatment of lung cancer, the identification and use of biomarkers to guide treatment decisions, and the patient and provider experience of managing this challenging disease.

The Lung Cancer Journey is associated with MDedge Hematology & Oncology, the source for timely, relevant, evidence-based, practice-changing information for hematologist-oncologists and medical oncologists. Readily accessible, interactive formats make MDedge Hematology & Oncology the best way for busy specialists to stay up to date and gain the perspectives they need to provide state-of-the-art care that improves patient outcomes.

MDedge Hematology & Oncology (www.mdedge.com/hematology-oncology) is owned by Frontline Medical Communications.

About Frontline Medical Communications

Frontline Medical Communications (Frontline) serves more than 1.2 million physicians and other health care professionals with diverse print and interactive multimedia products and platforms, and live events.

More than 30 enduring specialty journal brands offer a powerful synergy, including indexed, clinical, practical, and daily news-oriented content in Allergy, Cardiology, Dermatology, Emergency Medicine, Endocrinology/Diabetology, Family Medicine, Federal clinical medicine, Gastroenterology, Geriatrics, Internal Medicine, Neurology, Nurse Practitioners, Physician Assistants, Obstetrics/ Gynecology, Oncology/Hematology, Orthopedic Surgery, Pain Medicine, Pediatrics, Primary care, Psychiatry, Pulmonology, Rheumatology, General Surgery, Vascular Surgery, and Thoracic Surgery.